Replies to post #550300 on NorthWest Biotherapeutics Inc (NWBO)

[learningcurve2020]

QL300,

That goes without saying but doesn't change investors current need to know.

"We may never know what happened with the enrollment halt. If they get approval, I don’t think many people will care."

Interesting nobody chimed in on your reply on the Federal Rule. I'm guessing that spoofing is illegal whether or not the target company ever had or will have a real revenue generating product?? Therefor any discovery in a spoofing case must not include a peek under the hood of said target company, true? Hmm.

>>Discovery is extremely broad. This is the official Federal Rule: Parties may obtain discovery regarding any nonprivileged matter that is relevant to any party's claim or defense and proportional to the needs of the case, considering the importance of the issues at stake in the action, the amount in controversy, the parties’ relative access to relevant information, the parties’ resources, the importance of the discovery in resolving the issues, and whether the burden or expense of the proposed discovery outweighs its likely benefit. Information within this scope of discovery need not be admissible in evidence to be discoverable.

Hey Bio,

I'm skeptical of your take on the enrollment halt. And, what about now after unblinding, wouldn't you want to read your explanation in JAMA? You're really saying from 2009 to 2014 patients were seen to be living longer in a very short lived disease but for some reason the endpoint remained PFS as the trial went for another whopping five years with no commercialization into 2022!...And, no real compassionate use stats either? Leukaphersis or not the trial was set up as a randomized so they knew the options. It was only upon progression the chemo-rad arm could move to the treatment arm. Wouldn't patients fortunate enough to have a total resection go with SOP until the tumor showed signs of return?? I'm pretty certain that'd be a personal physician's advice with an experimental vaccine. Sorry, but something just doesn't smell right on the inability to fill the control arm. Personally, I think it has more to do with the screening caught late, and perhaps sending those who failed the criteria on to the study trial or pay compassionate use.